{
    "clinical_study": {
        "@rank": "107515", 
        "arm_group": [
            {
                "arm_group_label": "KAM2904 Face Cream and KAM3008  Body Lotion", 
                "arm_group_type": "Experimental", 
                "description": "A group treated with KAM2904 Face Cream and KAM3008  Body Lotion"
            }, 
            {
                "arm_group_label": "petrolatum-based moisturizer", 
                "arm_group_type": "Sham Comparator", 
                "description": "control group"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to demonstrate the safety and efficacy of KAM2904 Face\n      Cream and KAM3008 Body Lotion in reducing the symptoms of mild to moderate AD. Efficacy will\n      be evaluated by comparing SCORAD and Eczema Area Severity Index (EASI) in a group of\n      subjects treated with KAM2904 Face Cream and KAM3008 Body Lotion (the treatment group),\n      versus a group of subjects treated with a petrolatum-based moisturizer  (the control group).\n      Safety will be determined by the number and severity of Adverse Events Device-Related."
        }, 
        "brief_title": "Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD)", 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 Male or female between 2 and 12 years of age\n\n               -  The subject suffers from moderate atopic dermatitis (SCORAD<40) that is amenable\n                  to treatment\n\n               -  Diagnosis of atopic dermatitis meets Hanifin's criteria (at least 3 basic\n                  features and at least 3 minor features)\n\n               -  Atopic dermatitis is, in the opinion of the investigator, stable for the past 7\n                  days\n\n               -  The subject's parents are able to apply the study product twice a day (each\n                  morning and evening) for a consecutive period of 42 days\n\n               -  The subject's parents agree that the subject will not change his/her lifestyle\n                  during the study period (including: regular body hygiene product (soap), the\n                  number of baths and showers per day, the laundry detergent and fabric softener\n                  used to wash clothes)\n\n               -  The subject's parents agree to use only the test product during the study period\n\n               -  The subject's legal guardian is able and willing to sign the informed consent\n                  form and to comply with the study regulations of this protocol\n\n        Exclusion Criteria:\n\n          -  \u2022 The subject has another dermatological disease/condition that could interfere with\n             the clinical evaluation, including infected atopic dermatitis lesions\n\n               -  The subject has a previous history of allergy to cosmetic products or to any of\n                  the ingredients included in the tested formulations (Appendices 1 and 2)\n\n               -  The subject received a topical or a systemic immune-modulator (such calcineurin\n                  inhibitors  or cortico-steroids)  for the treatment of atopic dermatitis, within\n                  14 days prior to day 0\n\n               -  The subject underwent phototherapy within 28 days prior to day 0\n\n               -  The subject is expected to be extensively exposed to the sun during the trial\n\n               -  The subject underwent any experimental treatment within 14 days prior to day 0"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01781663", 
            "org_study_id": "KAM-ATOPIC-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "KAM2904 Face Cream and KAM3008  Body Lotion", 
                "intervention_name": "KAM2904 Face Cream", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "KAM2904 Face Cream and KAM3008  Body Lotion", 
                "intervention_name": "KAM3008 Body Lotion", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "petrolatum-based moisturizer", 
                "intervention_name": "petrolatum-based moisturizer", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Petrolatum"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 29, 2014", 
        "link": {
            "description": "Sponsor's site", 
            "url": "http://www.kamedis.com"
        }, 
        "location": {
            "contact": {
                "last_name": "Dr. Carlos Marin, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain"
                }, 
                "name": "Fundaci\u00f3n Teknon"
            }, 
            "investigator": {
                "last_name": "Dr. Carlos Marin, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "mirisani@013.net", 
            "last_name": "Miri Sani"
        }, 
        "overall_official": {
            "affiliation": "Tel Aviv Soraski Medical Center - Dermatology Unit", 
            "last_name": "Prof. Eli Sprecher, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "\u2022 Change in SCORAD (Scoring Atopic Dermatitis)", 
                "safety_issue": "No", 
                "time_frame": "after 42 days of treatment"
            }, 
            {
                "measure": "\u2022 Change in EASI (Eczema Area Severity Index)", 
                "safety_issue": "No", 
                "time_frame": "after 42 days of treatment"
            }, 
            {
                "measure": "\u2022 Change in the scoring of individual symptoms of atopic dermatitis", 
                "safety_issue": "No", 
                "time_frame": "after 42 days of treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01781663"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "\u2022 Trend in the change of SCORAD", 
                "safety_issue": "No", 
                "time_frame": "after 42 days of treatment"
            }, 
            {
                "measure": "\u2022 Trend in the change of EASI", 
                "safety_issue": "No", 
                "time_frame": "after 42 days of treatment"
            }, 
            {
                "measure": "\u2022 Trend in the change of individual symptoms of atopic dermatitis", 
                "safety_issue": "No", 
                "time_frame": "after 42 days of treatment"
            }, 
            {
                "description": "Safety will be measured by the number and severity of Device-Related Adverse Events.", 
                "measure": "\u2022 Safety of KAM2904 Face Cream and KAM3008 Body Lotion", 
                "safety_issue": "Yes", 
                "time_frame": "days D14, D28, D42 and unscheduled visits"
            }
        ], 
        "source": "Kamedis Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kamedis Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}